PF 4995274

Drug Profile

PF 4995274

Alternative Names: PF-04995274; PF-4995274

Latest Information Update: 22 Dec 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Antidementias
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 10 Nov 2011 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 10 Nov 2011 Discontinued - Phase-I for Alzheimer's disease in Belgium (PO)
  • 12 Oct 2011 Pfizer terminates a phase I trial in Healthy volunteers in the USA (NCT01345864)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top